Life Science Market Size, Report by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Life Science Market

5.1. COVID-19 Landscape: Life Science Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Life Science Market, By Type

8.1. Life Science Market Revenue and Volume Forecast, by Type

8.1.1. Biotechnology

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Pharmaceuticals

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Medical Devices

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Life Science Tools

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Digital Health Solutions

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Life Science Market, By Applications

9.1. Life Science Market Revenue and Volume Forecast, by Applications

9.1.1. Diagnostics

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Therapeutics

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Clinical Trials

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Research & Development

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Life Science Market, By Therapeutic Areas

10.1. Life Science Market Revenue and Volume Forecast, by Therapeutic Areas

10.1.1. Oncology

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Cardiology

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Neurology

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Immunology

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Rare Diseases

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Infectious Diseases

10.1.6.1. Market Revenue and Volume Forecast

10.1.7. Others

10.1.7.1. Market Revenue and Volume Forecast

Chapter 11. Global Life Science Market, By End-User

11.1. Life Science Market Revenue and Volume Forecast, by End-User

11.1.1. Pharmaceutical Companies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Biotechnology Companies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Academic & Research Institutions

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Hospitals & Clinics

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Others (Contract Research Organizations (CROs), and Government Organizations)

11.1.5.1. Market Revenue and Volume Forecast

Chapter 12. Global Life Science Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Type

12.1.2. Market Revenue and Volume Forecast, by Applications

12.1.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.1.4. Market Revenue and Volume Forecast, by End-User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Type

12.1.5.2. Market Revenue and Volume Forecast, by Applications

12.1.5.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.1.5.4. Market Revenue and Volume Forecast, by End-User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Type

12.1.6.2. Market Revenue and Volume Forecast, by Applications

12.1.6.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.1.6.4. Market Revenue and Volume Forecast, by End-User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Type

12.2.2. Market Revenue and Volume Forecast, by Applications

12.2.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.2.4. Market Revenue and Volume Forecast, by End-User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Type

12.2.5.2. Market Revenue and Volume Forecast, by Applications

12.2.5.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.2.5.4. Market Revenue and Volume Forecast, by End-User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Type

12.2.6.2. Market Revenue and Volume Forecast, by Applications

12.2.6.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.2.6.4. Market Revenue and Volume Forecast, by End-User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Type

12.2.7.2. Market Revenue and Volume Forecast, by Applications

12.2.7.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.2.7.4. Market Revenue and Volume Forecast, by End-User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Type

12.2.8.2. Market Revenue and Volume Forecast, by Applications

12.2.8.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.2.8.4. Market Revenue and Volume Forecast, by End-User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Type

12.3.2. Market Revenue and Volume Forecast, by Applications

12.3.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.3.4. Market Revenue and Volume Forecast, by End-User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Type

12.3.5.2. Market Revenue and Volume Forecast, by Applications

12.3.5.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.3.5.4. Market Revenue and Volume Forecast, by End-User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Type

12.3.6.2. Market Revenue and Volume Forecast, by Applications

12.3.6.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.3.6.4. Market Revenue and Volume Forecast, by End-User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Type

12.3.7.2. Market Revenue and Volume Forecast, by Applications

12.3.7.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.3.7.4. Market Revenue and Volume Forecast, by End-User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Type

12.3.8.2. Market Revenue and Volume Forecast, by Applications

12.3.8.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.3.8.4. Market Revenue and Volume Forecast, by End-User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Type

12.4.2. Market Revenue and Volume Forecast, by Applications

12.4.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.4.4. Market Revenue and Volume Forecast, by End-User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Type

12.4.5.2. Market Revenue and Volume Forecast, by Applications

12.4.5.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.4.5.4. Market Revenue and Volume Forecast, by End-User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Type

12.4.6.2. Market Revenue and Volume Forecast, by Applications

12.4.6.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.4.6.4. Market Revenue and Volume Forecast, by End-User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Type

12.4.7.2. Market Revenue and Volume Forecast, by Applications

12.4.7.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.4.7.4. Market Revenue and Volume Forecast, by End-User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Type

12.4.8.2. Market Revenue and Volume Forecast, by Applications

12.4.8.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.4.8.4. Market Revenue and Volume Forecast, by End-User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Type

12.5.2. Market Revenue and Volume Forecast, by Applications

12.5.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.5.4. Market Revenue and Volume Forecast, by End-User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Type

12.5.5.2. Market Revenue and Volume Forecast, by Applications

12.5.5.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.5.5.4. Market Revenue and Volume Forecast, by End-User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Type

12.5.6.2. Market Revenue and Volume Forecast, by Applications

12.5.6.3. Market Revenue and Volume Forecast, by Therapeutic Areas

12.5.6.4. Market Revenue and Volume Forecast, by End-User

Chapter 13. Company Profiles

13.1. Thermo Fisher Scientific Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Danaher Corporation

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Roche Holding AGMerck KGaA (MilliporeSigma)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Pfizer Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Johnson & Johnson

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Agilent Technologies Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Illumina, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Becton

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Dickinson and Company (BD)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Bio-Rad Laboratories, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The life science market is expected to grow at a compound annual growth rate (CAGR) of around 10.32% from 2025 to 2034.

The major players in the life science market include Thermo Fisher Scientific Inc., Danaher Corporation, Roche Holding AGMerck KGaA (MilliporeSigma), Pfizer Inc., Johnson & Johnson, Agilent Technologies Inc., Illumina, Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Abbott Laboratories, and GE HealthCare.

The driving factors of the life science market are the advancements and innovations like gene editing, next-generation sequencing, and AI are transforming research and development in various life science applications

North America region will lead the global life science market during the forecast period 2025 to 2034.